Company Guardant Health, Inc.

Equities

GH

US40131M1099

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 21:00:00 12/02/2026 GMT			5-day change	1st Jan Change
102.76 ^USD	-4.48%		+4.47%	+0.61%

02-02	Guardant Health, Inc. Announces Publication of the Largest Study to Date Evaluating Circulating Tumors forMRD Detection in Patients with Rescted Stage III Colon Cancer After Surgery and Before Adjuvant Chemotherapy	CI
01-30	UBS Adjusts Price Target on Guardant Health to $175 From $110, Maintains Buy Rating	MT

Business description: Guardant Health, Inc.

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

Number of employees: 2,010

Sales by Activity: Guardant Health, Inc.

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
Medical Labs & Research	287M	374M	450M	564M	739M

See all business segments

Geographical breakdown of sales: Guardant Health, Inc.

Fiscal Period: December	2020 (USD)	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)
United States	265M	353M	421M	527M	697M
International	22.07M	21.09M	28.92M	37.42M	41.85M

See all geographic segments

Executive Committee: Guardant Health, Inc.

Manager	Title	Age	Since
Michael Wiley DFI	Director of Finance/CFO	50	31/12/2012
AmirAli Talasaz CEO	Chief Executive Officer	46	04/08/2021
Helmy Eltoukhy CEO	Chief Executive Officer	47	31/12/2012
Michael Bell DFI	Director of Finance/CFO	57	04/01/2021
Gulshan H. Shaver CMP	Compliance Officer	-	30/04/2023

See GUARDANT HEALTH, INC. governance

Composition of the Board of Directors: Guardant Health, Inc.

Director	Title	Age	Since
Helmy Eltoukhy CHM	Chairman	47	04/08/2021
AmirAli Talasaz CHM	Chairman	46	31/12/2012
Ian Clark BRD	Director/Board Member	64	30/11/2016
Vijaya Gadde BRD	Director/Board Member	51	31/05/2020
Meghan Joyce BRD	Director/Board Member	42	03/08/2021
Myrtle Potter BRD	Director/Board Member	67	14/10/2021
Steve Krognes BRD	Director/Board Member	57	29/06/2022
Musa Tariq BRD	Director/Board Member	43	05/03/2023
Manuel Medina BRD	Director/Board Member	58	16/07/2024
Roberto Mignone BRD	Director/Board Member	54	20/10/2024

Composition of the Board of Directors

Shareholders: Guardant Health, Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 9.4 %	12,160,768	9.4 %	1 387 M $
BlackRock Advisors LLC 7.916 %	10,240,933	7.916 %	1 168 M $
Invesco Advisers, Inc. 3.81 %	4,929,543	3.81 %	562 M $
Baillie Gifford & Co. 3.78 %	4,890,026	3.78 %	558 M $
T. Rowe Price International Ltd. 3.263 %	4,221,637	3.263 %	481 M $

List of GUARDANT HEALTH, INC. shareholders

Holdings: Guardant Health, Inc.

Name	Equities	%	Valuation
LUNIT INC. 3.93%	1,150,000	3.93%	32 M $

Company details: Guardant Health, Inc.

Guardant Health, Inc.

3100 Hanover Street

94304, Palo Alto

+855 698 8887

http://www.guardanthealth.com

Diagnostic & Testing Substances

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
GUARDANT HEALTH, INC.	-4.48%	+4.47%	+126.44%	+267.13%	13.24B
BIOMÉRIEUX	+0.38%	-1.74%	-18.22%	-3.25%	13B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-1.85%	-3.66%	-17.47%	-15.35%	5.97B
CARIS LIFE SCIENCES, INC.	-3.95%	-2.82%	-	-	5.83B
DIASORIN S.P.A.	-0.35%	+0.63%	-26.35%	-36.94%	4.75B
LANTHEUS HOLDINGS, INC.	+2.14%	+5.95%	-16.30%	+17.93%	4.56B
AUTOBIO DIAGNOSTICS CO., LTD.	-0.55%	-1.33%	-10.88%	-48.20%	3B
ANDON HEALTH CO., LTD.	+0.19%	+1.11%	-2.49%	-19.34%	2.55B
10X GENOMICS, INC.	-8.56%	-1.07%	+45.92%	-59.67%	2.22B
BEIJING HOTGEN BIOTECH CO., LTD.	-1.55%	+1.53%	+116.76%	+125.46%	1.78B
Average	-1.86%	-0.12%	+21.93%	+25.31%	5.69B
Weighted average by Cap.	-1.81%	-0.28%	+27.50%	+62.79%